CORAL SPRINGS, Florida, November 24, 2014 /PRNewswire/ --
Legal Marijuana & Cannabis Industry lean more toward heavily capitalized investors as Leading Technology & MMJ Manufacturers set sights on the Mainstream and becoming more socially acceptable. Major MMJ Companies in focus today are: Surna Inc. (OTC: SRNA), Medical Marijuana Inc. (OTC: MJNA), Hemp, Inc. (OTC: HEMP), Cannabis Science, Inc. (OTC: CBIS) and Nuvilex, Inc. (OTC: NVLX)
Surna Inc. ( OTCQB: SRNA), an engineering and manufacturing firm that develops, acquires, produces and sells disruptive technology with a current focus on the legal marijuana industry recently reported third quarter financial results.
Surna CFO Doug McKinnon stated, "As expected, Company fundamentals are now reflected in our technical financials. Gross revenues have increased in excess of 330% from Q2 to Q3, from $340,000 to $1,200,000. When the revenues from our most recent acquisition are factored in, total revenues exceeded $1,800,000, or an increase in excess of 520%. A 40% year-to-date gross margin was also achieved.".
Read the full SRNA press release at http://www.financialnewsmedia.com/profiles/srna.html
Surna's research and development engineers are creating advanced technologies intended to retool the cannabis industry. The Company is also aggressively pursuing the most promising acquisitions in the cannabis sector. Surna CEO and Zynga Co-Founder Tom Bollich was recently featured on CNNMoney for his highly publicized segue into cannabis grow technology.
Medical Marijuana, Inc. (OTC Pink: MJNA) is pleased to inform shareholders and the general public that its portfolio companies were featured in news media reports from the 3rd annual Marijuana Business Conference held Nov. 12-14th in Las Vegas. As told by NBC3's Kelsey Thomas, the conference grew to host more than 2,000 attendees and feature 125 exhibitors. Fueling attendee interest was, according to MMJ Business Daily, "The Nevada Department of Health and Human Services on Monday awarded 55 preliminary licenses for dispensaries and more than 300 for permits [for] other types of medical cannabis businesses."
Hemp, Inc.'s (OTC Pink: HEMP) wholly owned subsidiary, The Industrial Hemp and Medical Marijuana Consulting Company, Inc. (IHMMCC), is announced this month that it has signed a consultant agreement with VaporBrands International, Inc. (OTC: VAPR), a leading company focused on the development and ownership of electronic cigarette brands. Per the Consultant Agreement, IHMMCC will provide product distribution, professional sales and marketing services, and sales representation for VaporBrands to the medical marijuana and industrial hemp industries, as well as source partnerships for international expansion and other traditional channels of distribution.
In a move that signals a forceful reinvestment in the largest legal medical cannabis market, Cannabis Science, Inc. ( OTCQB: CBIS), a U.S. company specializing in global cannabis formulation-based drug development and consulting, has successfully renegotiated its agreement with Apothecary Genetics Investments LLC to purchase and license two northern California production farms with a combined total of 51 acres. The purchase includes all related equipment for cannabis cultivation and production for the state's substantial medical cannabis market.
Nuvilex, Inc. ( OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that it has formed a "Diabetes Consortium" that will be tasked with the development of Nuvilex's treatment for insulin-dependent diabetes. The composition of the Diabetes Consortium has evolved over many months. In addition to key personnel from Nuvilex, it consists of principals from Austrianova - Prof. Dr. Walter H. Gunzburg, the Chief Technical Officer of Austrianova and Nuvilex's Chief Scientific Officer, Dr. Brian Salmons, the CEO of Austrianova (Drs. Gunzburg and Salmons co-developed the Cell-in-a-Box(R) technology) and Prof. Ann Simpson of the University of Technology Sydney (UTS) who, along with her professional colleagues at UTS, developed the insulin-producing cells known as Melligen cells. The plan is for these cells to be used as part of Nuvilex's diabetes treatment.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter:http://twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated one thousand five hundred dollars for news coverage of the current press release issued by Surna, Inc. by a non-affiliated third party. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
SOURCE FN Media Group, LLC